Design Therapeutics, Inc. (DSGN) vs Gyre Therapeutics, Inc. (GYRE)

A side-by-side comparison of Design Therapeutics, Inc. and Gyre Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare

Total return — DSGN vs GYRE

growth of $100 · dividends reinvested · last 6y
DSGN -70.1% (-18.2%/yr)GYRE -30.7% (-5.9%/yr)GYRE compounded faster over this window
050100150200250Start $10020222023202420252026$30$69
DSGN GYRE

DSGN vs GYRE: by the numbers

  • •GYRE is the larger company ($808M vs $745M market cap).
  • •Both run net losses; DSGN's is the smaller (0.00% vs -14.52% net margin).

Metrics side by side

Valuation

MetricDSGNGYRE
P/S ratioN/A6.77
P/B ratio3.697.49

Profitability

MetricDSGNGYRE
Gross margin0.00%94.30%
Operating margin0.00%9.86%
Net margin0.00%-14.52%
ROE-35.07%-13.30%
ROIC-38.92%-9.77%

Growth (annualized)

MetricDSGNGYRE
Revenue CAGR (5Y)N/A84.92%
Total return CAGR (5Y)-3.82%-0.34%

Frequently asked

How have DSGN and GYRE total returns compared?
Over the past 5 years, DSGN delivered -3.82% and GYRE delivered -0.34% annualized total return. Past performance doesn't predict future results.

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.